Avanos medical, inc. (AVNS)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Operating Activities
Net income (loss)

-45,900

57,500

79,300

39,800

-426,300

27,100

154,600

152,600

Depreciation and amortization

36,900

33,500

59,500

65,200

65,400

85,400

69,200

57,600

Stock-based compensation expense

10,500

10,500

12,600

14,800

14,100

7,900

6,000

5,300

Net non-cash gain on Divestiture

0

98,400

0

0

-

-

-

-

Goodwill impairment

-

-

-

-

474,000

0

0

-

Provision for losses on accounts receivable and inventories

-

-

-

-

-

-

-

-11,100

Deferred income taxes

-

-

-

-

-

-

-

-11,600

Asset impairment

-

-

-

-

-

41,900

0

0

Amortization of debt issue costs and debt discount

-

-

-

-

-

-

-

0

Net loss on asset dispositions

-600

-1,500

-3,300

-3,700

6,700

-6,700

-3,400

-100

Changes in operating assets and liabilities, net of acquisition:
Accounts receivable

800

-67,400

15,300

-8,400

-9,000

-15,100

19,500

-26,400

Inventories

21,300

34,500

16,800

-41,000

20,200

2,900

-14,300

15,100

Prepaid expenses and other assets

-30,800

45,700

2,300

-1,700

6,000

4,800

-2,000

900

Accounts payable

-83,600

-64,000

18,800

6,500

14,700

4,500

15,100

8,000

Accrued expenses

15,300

-66,600

11,300

34,000

-14,500

900

-23,800

-8,800

Deferred income taxes and other

17,000

6,800

6,200

26,300

5,900

33,900

2,500

100

Cash Used in Operating Activities

-74,500

-145,600

144,200

188,800

97,600

147,900

223,800

202,600

Investing Activities
Capital expenditures

50,600

49,100

43,200

29,100

70,400

78,500

49,000

40,800

Acquisition of assets and businesses, net of cash acquired

57,500

65,700

0

175,000

0

0

2,200

0

Proceeds from the Divestiture

0

754,300

0

0

-

-

-

-

Deposit received on pending sale of assets

-

-

-

-

-

-

-

0

Proceeds from Sale of Property, Plant, and Equipment

0

0

100

3,200

7,800

7,800

300

500

Cash Used in Investing Activities

-108,100

639,500

-43,100

-200,900

-62,600

-70,700

-50,900

-40,300

Financing Activities
Debt repayments

200

339,000

0

0

51,000

13,800

67,900

31,200

Line of credit facility proceeds

-

-

-

72,000

0

0

-

-

Line of credit facility repayments

-

-

-

72,000

0

0

-

-

Debt proceeds

-

-

-

-

-

638,000

4,000

7,100

Debt issuance costs

0

1,600

0

900

0

11,800

0

0

Purchases of treasury stock

3,600

900

2,500

900

1,000

0

0

-

Spin-off cash distribution to Kimberly-Clark

-

-

-

-

-

680,000

0

0

Net transfers from Kimberly-Clark

-

-

-

-

-

93,300

-119,300

-113,700

Other

-

-

-

-

-

3,500

3,200

3,900

Proceeds from the exercise of stock options

5,300

17,100

4,700

400

1,400

0

0

-

Cash Used in Financing Activities

1,500

-324,400

2,200

-1,400

-50,600

29,200

-180,000

-133,900

Effect of Exchange Rate Changes on Cash and Cash Equivalents

1,900

-4,700

2,700

-2,300

-3,900

-1,500

3,300

-600

Decrease in Cash and Cash Equivalents

-179,200

164,800

106,000

-15,800

-19,500

104,900

-3,800

27,800

Supplemental Cash Flow Disclosure:
Cash paid for income taxes

8,400

96,600

21,400

29,100

43,300

87,600

74,200

94,300

Cash paid for interest

16,700

20,600

28,700

29,900

32,600

0

0

-

Supplemental Noncash Disclosure
Capital Expenditures Incurred but Not yet Paid

11,200

16,900

4,500

5,800

5,600

21,500

0

-